Trial Profile
A phase 2 study of MultiStem cell therapy for early treatment and prevention of complications after severe traumatic injury
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Invimestrocel (Primary)
- Indications Traumatic brain injuries
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms MATRICS-1
- 01 Jun 2023 According to an Athersys media release, this trial is supported in part by MTEC (Medical Technology Enterprise Consortium) in partnership with the Department of Defense, and funding from Memorial Hermann Foundation.
- 01 Jun 2023 According to an Athersys media release, patient enrollment has begun in the third and final cohort in this trial, and approximately 140 patients will be enrolled in cohort three.
- 18 May 2023 According to Athersys media release, Completed DSMB review of cohort 1 & 2 of MATRICS trauma trial using both cell factory and bioreactor manufactured clinical product.